Johnson & Johnson: Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis
Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...
J&J gets Priority Review designation for nipocalimab BLA
Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for ...
Mabwell's Nectin-4 Targeted ADC 9MW2821 Combination Therapy Demonstrates 87.5% ORR and Granted CDE Breakthrough Therapy Designation
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced a significant milestone for its proprietary Nectin-4 targeted ADC (9MW2821). On January 8, 2025, ...
Therapy left me drained and negative – will a life coach be different?
My tailored session combined life coaching, hypnotherapy, meditation, breathwork, vision-crafting skills and strategic ...
Crain's New York8h
Mount Sinai and Memorial Sloan Kettering advance AI tool for new cancer treatment
Researchers at Mount Sinai and Memorial Sloan Kettering believe they’ve made a breakthrough in a new form of cancer treatment ...
STAT8h
German research team’s discoveries open new possibilities for patients with autoimmune diseases
A German research team’s discoveries about autoimmune diseases are opening up new possibilities for patients with lupus and ...
STAT22h
Scribe Therapeutics becomes latest CRISPR company to announce layoffs
Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...
today.ucsd23h
UC San Diego Health First to Offer Novel Gene Therapy for Hemophilia B
UC San Diego Health is one of a few health care systems on the West Coast to offer a new gene therapy for hemophilia B, a ...